Top Markets
#1 Bedrock Bedrock +42.72%
#2 Naoris Protocol Naoris Protocol +24.89%
#3 pippin pippin +18.20%
#4 IQ IQ +17.47%
#5 Bitway Bitway +17.00%
#6 Irys Irys +15.43%
#7 Resolv RLP Resolv RLP +10.78%
#8 Chrema Coin Chrema Coin +10.28%
#9 peaq peaq +9.87%
#10 Green Green +8.39%
Coin of the day
Bedrock Bedrock
Settings
Language
ENGLISH
Currency
USD
Theme
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rank in Stocks #20441
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Share Price
$0.16328419
Market Cap
$204.14K
Change (1 day)
4.35%
Change (1 year)
102.45%
Country
GB
Trade Fusion Antibodies plc (FAB)

Category

Healthcare
P/E ratio for Fusion Antibodies plc (FAB)
P/E ratio as of March 2026 TTM: -9.65
According to Fusion Antibodies plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.65. At the end of 2024 the company had a P/E ratio of -0.96.
P/E ratio history for Fusion Antibodies plc from 2013 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -9.65 180.42%
2025 -3.44 258.24%
2024 -0.96 -75.09%
2023 -3.86 -70.26%
2022 -12.97 -5.91%
2021 -13.79 -54.21%
2020 -30.11 504.68%
2019 -4.98 -79.50%
2018 -24.29 -110.68%
2017 227.44 862.11%
2016 23.64 -107.37%
2015 -320.55 33.40%
2014 -240.30 312.85%
2013 -58.20 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -211.10%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 -412.49%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -276.59%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -415.54%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 38.30 -497.06%
NL
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.